Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Asmita Chopra"'
Autor:
Alessandro Paniccia, Derek Barclay, Yoram Vodovotz, Jacob C. Hodges, Michael T. Lotze, Pranav Murthy, Amer H. Zureikat, Brian A. Boone, Randall E. Brand, Ruben Zamora, Kenneth K. Lee, Asmita Chopra, Richard L. Simmons
Publikováno v:
J Immunother
Despite its increased application in pancreatic ductal adenocarcinoma (PDAC), complete response to neoadjuvant therapy (NAT) is rare. Given the critical role of host immunity in regulating cancer, we sought to correlate baseline inflammatory profiles
Autor:
M.E. Hogg, Brian A. Boone, Kenneth K. Lee, Alessandro Paniccia, Nathan Bahary, Susannah G. Ellsworth, Amer H. Zureikat, Joal D. Beane, David L. Bartlett, Asmita Chopra, Michael T. Lotze, Aatur D. Singhi, Herbert J. Zeh, Adam C. Olson, Jacob C. Hodges, Steve Burton
Publikováno v:
Ann Surg Oncol
BACKGROUND. Neoadjuvant therapy is increasingly used for patients with pancreatic ductal adenocarcinoma (PDAC). It is unknown whether neoadjuvant chemoradiotherapy is more effective than chemotherapy (NCRT vs. NAC). We aim to compare pathological and
Autor:
Asmita, Chopra, Joal D, Beane
Publikováno v:
Annals of surgical oncology. 28(12)
Autor:
Caroline J. Rieser, David L. Bartlett, Asmita Chopra, Kenneth K.W. Lee, Sowmya Narayanan, Amer H. Zureikat, Alessandro Paniccia, Samer AlMasri, Tracy Daum, Mazen S. Zenati, Katelyn Smith, Nathan Bahary, Vivianne Oyefusi, Ibrahim Nassour
Publikováno v:
J Surg Oncol
BACKGROUND AND OBJECTIVES Neoadjuvant chemotherapy (NAT) for pancreatic adenocarcinoma (PDAC) is increasingly being utilized. However, a significant number of patients will experience early recurrence, possibly negating the benefit of surgery. We aim
Autor:
Asmita, Chopra, Mazen, Zenati, Melissa E, Hogg, Herbert J, Zeh, David L, Bartlett, Nathan, Bahary, Amer H, Zureikat, Joal D, Beane
Publikováno v:
Annals of surgical oncology. 28(12)
A positive microscopic margin (R1) following resection of pancreatic ductal adenocarcinoma (PDAC) can occur in up to 80% of patients and is associated with reduced survival and increased recurrence. Our aim was to characterize the impact of neoadjuva
Publikováno v:
Updates in surgery. 73(3)
The utilization of minimally invasive distal pancreatectomy (MIDP) is increasing, yet debate remains regarding its oncologic safety in the setting of pancreatic adenocarcinoma (PDAC). Herein we present our institutional experience with robotic (RDP),
Autor:
Kenneth K.W. Lee, Alessandro Paniccia, Katelyn Smith, Mazen S. Zenati, Melissa E. Hogg, Amr I. Al Abbas, James A. Brown, Amer H. Zureikat, Asmita Chopra, Herbert J. Zeh, Richard L. Simmons
Publikováno v:
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 24(7)
Long-term complications following pancreatoduodenectomy (PD) can significantly impact quality of life and healthcare utilization. Most reports focus on short-term (within 90 days) PD outcomes; however, the incidence and risk factors for long-term com
Publikováno v:
The Surgical clinics of North America. 100(1)
Melanoma is an aggressive malignancy arising from melanocytes in the skin and rarely in extracutaneous sites. The understanding of pathology of melanoma has evolved over the years, with the initial classifications based on the clinical and microscopi